Goal
Best-studied peptides for mood & anxiety
Ranked by the strongest evidence rung each compound holds, with what the study measured beside it. 12 were checked; 3 produced a graded row.
Last updated
12 compounds were read against this goal's condition; 3 produced a graded row. The other 9 are named further down.
About this page's scope
The thinnest page in this namespace, and it is shipped at its real size rather than padded. One condition, three graded rows, and the two compounds most often sold for mood — Semax and DSIP — were read against it and hold no row.
The ranking, and the key it uses
Ordered by the best rung the compound holds anywhere in this goal; then by what that study measured; then by how many graded rows it holds here, as a tie-break only; then by name. There is no blended score — one number mixing the rung and what was measured would invent a third scale nothing was graded against. Every rung links to the rubric that assigned it.
Reading the strip
1 human RCT2 human observational3 human case series4 animal in vivo5 in vitro6 theoretical7 computational
A filled cell means at least one graded row at that rung. Its colour is what the strongest such study measured: direct outcome · surrogate marker · mechanistic only. An outlined cell means no row at that rung.
-
1 graded row, 1 source
-
Anxiety
human RCT Direct outcome In registered trials
- Who was studied
- adults with PTSD (CAPS >= 50), n=26 enrolled / 24 completed, 67% female, single intranasal dose per session; not a diagnosed anxiety-disorder population
A phase Ib double-blind, placebo-controlled crossover dose-ranging study measured the Beck Anxiety Inventory and STAI-State after a single intranasal dose of 1.4-9.6 mg during a trauma-script provocation; higher doses were associated with lower BAI scores, while STAI-State and IES-R showed non-significant trends. The population was PTSD, not generalised or social anxiety disorder, and a single dose in a provocation paradigm is not a treatment course; no repeated-dosing trial is on file.
Source PubMed Central 1 primary source read for this row
-
-
1 graded row, 1 source
-
Anxiety
human RCT Mechanistic only Not approved for this condition
- Who was studied
- men with generalised social anxiety disorder, n=17, plus 18 healthy male control participants; single dose, sessions at least 7 days apart
Recorded, and not evidence for this condition
A randomised, double-blind, placebo-controlled crossover study gave a single 24 IU intranasal dose and measured amygdala functional connectivity to fearful faces on fMRI. Anxiety scales (LSAS, BAI, STAI) were used only to characterise participants at baseline, not as treatment endpoints, so no study here measured whether anxiety symptoms changed; the link from an imaging signal to symptom relief is an argument, not a result. Oxytocin is approved for obstetric use, not for anxiety, in any jurisdiction on file.
Source PubMed Central 1 primary source read for this row
-
-
1 graded row, 1 source
-
Anxiety
human observational Direct outcome Approved for this condition
- Who was studied
- patients with generalised anxiety disorder or neurasthenia, n=62 (30 selank, 32 medazepam comparator), adolescent to middle-aged, sex not reported; treatment duration not reported in the abstract
A comparator-controlled trial measured anxiety directly with the Hamilton anxiety scale, the Zung scale and CGI, and reported anxiolytic effect similar to medazepam. Selank is registered as an anxiolytic in the Russian Federation only; there is no FDA or EMA approval for any condition. The report is published in Russian in Zh Nevrol Psikhiatr Im S S Korsakova and only the English abstract could be read, so blinding, randomisation method and trial duration are not on file; there is no placebo arm. Regraded from human_rct on the precedent set by the semax row on /conditions/stroke: where only a Russian-language abstract could be read and randomisation, blinding and a placebo arm are not on file, the rubric caps the grade at rung 2 until the full paper exists.
Source PubMed 1 primary source read for this row
-
Checked, and nothing on file
9 compounds were read against this condition and produced no gradeable row. They are named here rather than left off, because a list of 3 reads identically whether 3 survived 12 or 3 were all anyone thought of.
-
C-Max
No rung — nothing on file to grade
Checked against anxiety. No study meeting the rubric was found for any of them.
-
CRH (Corticotropin-Releasing Hormone) on anxiety
No rung — nothing on file to grade Not approved for this condition
CRH is given to provoke an anxiety and stress response, not to relieve one. The drug development in this area is CRH-1 receptor ANTAGONISTS, which are different compounds and mostly failed in phase II. No study administers CRH as a treatment for anxiety.
-
DSIP
No rung — nothing on file to grade
Checked against anxiety. No study meeting the rubric was found for any of them.
-
Epitalon
No rung — nothing on file to grade
Checked against anxiety. No study meeting the rubric was found for any of them.
-
Nociceptin
No rung — nothing on file to grade
Checked against anxiety. No study meeting the rubric was found for any of them.
-
PEA
No rung — nothing on file to grade
Checked against anxiety. No study meeting the rubric was found for any of them.
-
Semax
No rung — nothing on file to grade
Checked against anxiety. No study meeting the rubric was found for any of them.
-
Simonson Alpha 1
No rung — nothing on file to grade
Checked against anxiety. No study meeting the rubric was found for any of them.
-
Vasopressin on anxiety
No rung — nothing on file to grade Not approved for this condition
The trialled agents here are V1a receptor ANTAGONISTS, not vasopressin. No study administering vasopressin for anxiety with a clinical anxiety outcome was located.
What this page does not say
It reports what was measured, in whom, and how directly. It does not say what to take or at what dose, and a position here is a record of study depth rather than a reason to use anything. A compound at the top of this list is the most studied against these conditions; that is not the same claim as the most effective, and nothing on this page makes the second one.
Browse by goal
- Weight loss — 29 compounds with a graded row, from 48 checked
- Anti-ageing & metabolic — 16 compounds with a graded row, from 30 checked
- Muscle growth — 9 compounds with a graded row, from 20 checked
- Infection & immunity — 23 compounds with a graded row, from 30 checked
- Cardiovascular — 29 compounds with a graded row, from 33 checked
- Healing & recovery — 16 compounds with a graded row, from 29 checked
- Sexual health & fertility — 13 compounds with a graded row, from 28 checked
- Pain — 8 compounds with a graded row, from 19 checked
- Skin & hair — 9 compounds with a graded row, from 33 checked
- Brain & nerve recovery — 7 compounds with a graded row, from 15 checked
- Sleep — 9 compounds with a graded row, from 30 checked
- Cognition — 8 compounds with a graded row, from 43 checked
- Inflammation — 5 compounds with a graded row, from 23 checked
- Biological ageing — 8 compounds with a graded row, from 30 checked
- Gut health — 12 compounds with a graded row, from 27 checked